A 35-year-old Nasdaq ticker went dark this week — and five days earlier, the biggest trade policy shock in a generation landed on the supply chains behind it. Hologic completed its $18.3 billion Blackstone-TPG take-private, removing one of MedTech’s most recognizable names from the public market. “Liberation Day” tariffs — with rates reaching triple digits on Chinese imports — sent device supply chain teams scrambling through bills of materials. And Kandu Health published the first randomized controlled trial for its IpsiHand brain-computer interface, closing the evidence gap BCI rehab has needed to move from clearance to coverage. Welcome to Issue #12 of The MedTech Minute.
Top Stories
Story 01
On April 7, Blackstone and TPG completed their acquisition of Hologic (Nasdaq: HOLX), taking the 35-year-old public company private at up to $18.3 billion. Shareholders received $76 per share in cash plus a contingent value right of up to $3 per share, paid in two installments tied to Breast Health revenue targets. CEO Steve MacMillan retired immediately; former Baxter CEO José (Joe) Almeida takes the helm. (Source: Hologic press release, April 7, 2026; MedTech Dive)
Why It Matters: Blackstone and TPG are buying a near-monopoly portfolio — Genius 3D mammography, ThinPrep Pap, Aptima diagnostics — with 65%+ gross margins and per-procedure revenue hospitals can’t easily cancel. The CVR structure signals PE confidence the Breast Health franchise outperforms without quarterly earnings pressure.
M&A
PE Take-Private
Women’s Health
Why This Matters for Builders
This deal is a blueprint that will be replicated. PE firms are screening for three things: a clinically essential category without a mainstream competitor, recurring consumable revenue tied to a large installed base, and a focus premium — no conglomerate discount diluting the valuation. If you’re building in a singular, defensible category, your clinical focus is also your business moat — whether you plan to go public, get acquired, or stay independent.
Story 02
BCI devices for stroke rehab have accumulated open-label data for years, but without a control group, separating the device’s contribution from natural recovery was impossible — and that gap kept payers at arm’s length. Kandu Health closed it. The company published positive results from the first randomized controlled trial of its IpsiHand system — a non-invasive, FDA-cleared BCI that reads ipsilateral motor cortex signals and drives a robotic exoskeleton on the affected hand. The device targets an estimated 3.4 million Americans with chronic post-stroke upper-extremity dysfunction. (Source: Kandu Health press release, April 2026; American Stroke Association)
Why It Matters: Randomized evidence is what separates a clearance from a coverage decision — and every prior IpsiHand study lacked a control group. This RCT directly addresses that gap, giving neurologists and payers the evidence needed to justify prescribing and reimbursing at scale.
Clinical Trial
BCI / Neurotech
RCT Results
Market Movers
| Ticker | Company | Price | Wk Change |
|---|
| ISRG | Intuitive Surgical | $451.70 | ▲ 3.1% |
| SYK | Stryker | $332.07 | ▼ 1.2% |
| BDX | BD (Becton Dickinson) | $218.40 | ▼ 0.8% |
| JNJ | Johnson & Johnson | $154.80 | ▲ 1.1% |
| ABT | Abbott | $101.83 | ▼ 2.3% |
| ZBH | Zimmer Biomet | $91.40 | ▲ 0.4% |
| MDT ★ | Medtronic | $86.42 | ▼ 5.9% |
| EW | Edwards Lifesciences | $71.20 | ▼ 1.3% |
| GEHC | GE HealthCare | $69.73 | ▼ 1.0% |
| BSX | Boston Scientific | $62.82 | ▲ 0.5% |
★ Biggest Mover: MDT fell 5.9% as MiniMed separation overhang and Liberation Day tariff uncertainty weighed on diabetes device margins. ISRG gained 3.1% on PE-driven interest in focused surgical robotics franchises following the Hologic go-private. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of April 7, 2026. For illustrative purposes only.
Industry Shift
Shift 01
The April 2 “Liberation Day” announcement — sweeping reciprocal tariffs with country-specific rates reaching triple digits on Chinese imports — sent device companies scrambling to audit component exposure across China, Vietnam, and Malaysia. A simultaneous 100% tariff framework targeting imported patented pharmaceuticals added another layer: devices were framed as a separate category, but device companies share many of the same Asian manufacturing ecosystems as pharma. (Source: MedTech Dive; MedCity News)
Companies already absorbing Section 301 tariffs — AngioDynamics revised its full-year guidance to reflect $4–$6 million in annual tariff impact (Source: AngioDynamics Q3 FY2026 earnings) — now face a compounding cost environment. The signal: this administration is willing to use triple-digit rates as a negotiating tool, and every supply chain team is rerunning BOM geography scenarios.
Why It Matters: The risk isn’t this tariff package alone — it’s that escalation at this scale is structural. Companies that have already built U.S. or nearshore manufacturing optionality into their bills of materials hold a widening cost advantage.
Regulatory
Supply Chain
Trade Policy
Deep Dive
The PE Go-Private Playbook: What Hologic Tells Us About Who’s Next
The Blackstone-TPG deal articulates a PE screening framework worth internalizing. Three characteristics define the target profile. First, a defensible regulatory moat — clinical evidence and clearance timelines competitors can’t replicate in three years. Second, recurring consumable revenue — per-procedure income from an installed base the company controls, not one-time capital equipment sales. Third, a focus premium — every product shares the same customer base and clinical category, making the business modelable, predictable, and attractive to sponsors who want to underwrite five-year cash flows.
By that screen, the PE shopping list for MedTech is identifiable. Pure-play companies spun from conglomerate divestitures — the kind Issue #11 detailed with BD and Medtronic — are natural candidates. Focused diagnostic companies with high-margin, hard-to-replicate platforms fit the profile. Surgical device companies with large installed bases and high-utilization instrument ecosystems tick every box.
Hologic opened the door. The go-private wave that swept through pharma over the past two years is now moving into device. It won’t be the last company through it.
The Builder’s Take
Tariffs Are a Product Decision — Build for Them Now, or Rebuild Under Pressure Later
Most device founders treat supply chain as a procurement decision made after design lock. That was defensible before triple-digit tariffs became a standing policy instrument. Geographic manufacturing risk now needs to be designed around the same way regulatory risk is — before you finalize a contract manufacturer, not when the tariff environment shifts mid-program. Map qualified U.S. or nearshore alternatives before design freeze. Price that optionality into your Series A. The founders who build supply chain resilience into their products in 2026 hold a structural cost advantage when their competitors are scrambling to renegotiate CMO contracts under pressure.
Fun Fact & Trivia
💡 Fun Fact — The Startup That Made Women’s Health Worth $18 Billion
Before Hologic acquired Cytyc Corporation in 2007 for $6.2 billion, women’s health represented less than 2% of total U.S. medical device R&D investment. Cytyc had been founded in 1987 to challenge the conventional Pap smear — a diagnostic technique essentially unchanged since George Papanicolaou introduced it in 1941. The ThinPrep liquid-based Pap test was the first meaningful advance in cervical cancer screening in 46 years. That single bet on a 36-year-old startup disrupting a 46-year-old test eventually compounded into the $18.3 billion platform that just went private this week.
MedTech Trivia
Hologic’s Genius 3D mammography platform was the first of its kind to receive FDA approval for breast cancer screening, and it uses a specific imaging technology that creates layered X-ray slices through breast tissue. What is this technology called — and what year did Hologic first receive FDA approval for it?
👇 Scroll to the footer for the answer
MedTech Word Search
🧩 Find the Hidden MedTech Terms, Click to Highlight
HOLOGIC
BLACKSTONE
IPSIHAND
STROKE
TARIFF
PRIVATE
Words hidden horizontally (→) and vertically (↓). Click letters to mark your finds.
Quick Question
Is the PE go-private wave good or bad for MedTech innovation? Hologic will build without Wall Street watching every quarter — but private companies also have less transparency, less liquidity for early investors, and different incentives for long-term R&D. Public or private: where does the next phase of MedTech get built best? Hit reply, I read every response.
Sponsor
